CLAIMS

1. An isolated or recombinant monoclonal antibody comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein the antibody agonizes or promotes one or more of the effects of human VISTA on T cell immunity, which antibody comprises a human IgG2 Fc or constant region which binds to Fc gamma receptors (FcγRs) at least including human CD32A; and wherein the variable region antibody of said antibody comprises:

(i) the $V_H$ CDRs of SEQ ID NO:140, 141 and 142 and the $V_L$ CDRs of SEQ ID NO:143, 144 and 145;
(ii) the $V_H$ CDRs of SEQ ID NO:400, 401 and 402 and the $V_L$ CDRs of SEQ ID NO:403, 404 and 405;
(iii) the $V_H$ CDRs of SEQ ID NO:470, 471 and 472 and the $V_L$ CDRs of SEQ ID NO:473, 474 and 475;
(iv) the $V_H$ CDRs of SEQ ID NO:770, 771 and 772 and the $V_L$ CDRs of SEQ ID NO:773, 774 and 775;
(v) the $V_H$ CDRs of SEQ ID NO:200, 201 and 202 and the $V_L$ CDRs of SEQ ID NO:203, 204 and 205;
(vi) the $V_H$ CDRs of SEQ ID NO:370, 371 and 372 and the $V_L$ CDRs of SEQ ID NO:373, 374 and 375;
(vii) the $V_H$ CDRs of SEQ ID NO:380, 381 and 382 and the $V_L$ CDRs of SEQ ID NO:383, 384 and 385;
(viii) the $V_H$ CDRs of SEQ ID NO:500, 501 and 502 and the $V_L$ CDRs of SEQ ID NO:503, 504 and 505;
(ix) the $V_H$ CDRs of SEQ ID NO:740, 741 and 742 and the $V_L$ CDRs of SEQ ID NO:743, 744 and 745.

2. The isolated or recombinant monoclonal antibody of claim 1, wherein the variable region antibody of said antibody comprises:

(i) a $V_H$ polypeptide of SEQ ID NO:106 and a $V_L$ polypeptide of SEQ ID NO:108;
(ii) a $V_H$ polypeptide of SEQ ID NO:406 and a $V_L$ polypeptide of SEQ ID NO:408;
(iii) a $V_H$ polypeptide of SEQ ID NO:476 and a $V_L$ polypeptide of SEQ ID NO:478;
(iv) a $V_H$ polypeptide of SEQ ID NO:776, and a $V_L$ polypeptide of SEQ ID NO:778;
(v) a $V_H$ polypeptide of SEQ ID NO:206 and a $V_L$ polypeptide of SEQ ID NO:208;
(vi) a $V_H$ polypeptide of SEQ ID NO:376 and a $V_L$ polypeptide of SEQ ID NO:378;
(vii) a $V_H$ polypeptide of SEQ ID NO:386 and a $V_L$ polypeptide of SEQ ID NO:388;

(viii) a $V_H$ polypeptide of SEQ ID NO:506 and a $V_L$ polypeptide of SEQ ID NO:508; or
(ix) a $V_H$ polypeptide of SEQ ID NO:746 and a $V_L$ polypeptide of SEQ ID NO:748.

3. The isolated or recombinant monoclonal antibody of claim 1, wherein said antibody comprises:

(i) the $V_H$ CDRs of SEQ ID NO:400, 401 and 402 and the $V_L$ CDRs of SEQ ID NO:403, 404 and 405;
(ii) the $V_H$ CDRs of SEQ ID NO:470, 471 and 472 and the $V_L$ CDRs of SEQ ID NO:473, 474 and 475;
(iii) the $V_H$ CDRs of SEQ ID NO:370, 371 and 372 and the $V_L$ CDRs of SEQ ID NO:373, 374 and 375;
(iv) the $V_H$ CDRs of SEQ ID NO:380, 381 and 382 and the $V_L$ CDRs of SEQ ID NO:383, 384 and 385; or
(v) the $V_H$ CDRs of SEQ ID NO:740, 741 and 742 and the $V_L$ CDRs of SEQ ID NO:743, 744 and 745.

4. The isolated or recombinant monoclonal antibody of claim 3, wherein said antibody comprises:

(i) a $V_H$ polypeptide of SEQ ID NO:406 and a $V_L$ polypeptide of SEQ ID NO:408;
(ii) a $V_H$ polypeptide of SEQ ID NO:476 and a $V_L$ polypeptide of SEQ ID NO: 478;
(iii) a $V_H$ polypeptide of SEQ ID NO:376 and a $V_L$ polypeptide of SEQ ID NO:378;
(iv) a $V_H$ polypeptide of SEQ ID NO:386 and a $V_L$ polypeptide of SEQ ID NO:388; or
(v) a $V_H$ polypeptide of SEQ ID NO:746 and a $V_L$ polypeptide of SEQ ID NO:748.

5. The antibody of claim 1, wherein the human lgG2 Fc or constant region comprises native human lgG2 binding to said FcγRs.

6. The antibody of any one of claims 1-5, which is human or humanized.

7. The antibody of any one of claims 1-5, which (i) comprises an lgG2 Fc region wherein either or both of the heavy chain cysteine residue at position 127 and the light chain cysteine residue at position 214 (wherein numbering is according to Kabat) are deleted or changed to a different amino acid residue, resulting in an increase in the agonistic properties of the resultant modified antibody relative to an antibody wherein these residues are unchanged, (ii) the cysteine residue at position 214 in the H2 region of said antibody is mutated or substituted with another amino acid and/or one or more of the cysteine residues at positions 127, 232 or 233 of the heavy chain are deleted or substituted with another amino acid, or (iii) it comprises

a human lgG2 constant domain wherein at least one cysteine residue is deleted or changed to another amino acid.

8. The antibody of any one of claims 1-5, wherein the antibody has an affinity or $K_D$ for human VISTA which is 50nM or less as determined by surface plasmon resonance at 37° C.

9. The antibody of any one of claims 1-5, wherein the antibody has an affinity or $K_D$ for human VISTA which is 1 nM or less as determined by surface plasmon resonance at 37° C.

10. A pharmaceutical composition comprising at least one antibody according to any one of claims 1-5.